In the last trading session, 1.29 million shares of the Nektar Therapeutics (NASDAQ:NKTR) were traded, and its beta was 0.65. Most recently the company’s share price was $0.80, and it changed around -$0.04 or -4.54% from the last close, which brings the market valuation of the company to $147.91M. NKTR currently trades at a discount to its 52-week high of $1.93, offering almost -141.25% off that amount. The share price’s 52-week low was $0.65, which indicates that the current value has risen by an impressive 18.75% since then.
Nektar Therapeutics stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 3 recommended NKTR as a Hold, whereas 2 deemed it a Buy, and 1 rated it as Underweight. Nektar Therapeutics is expected to report earnings per share of -0.19 for the current quarter.
Nektar Therapeutics (NASDAQ:NKTR) trade information
Instantly NKTR has showed a red trend with a performance of -4.54% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 0.9191 on recent trading dayincreased the stock’s daily price by 12.96%. The company’s shares are currently down -13.77% year-to-date, but still down -5.10% over the last five days. On the other hand, Nektar Therapeutics (NASDAQ:NKTR) is -5.73% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $18.5, which translates to bulls needing to increase their stock price by 95.68% from its current value. Analyst projections state that NKTR is forecast to be at a low of $6 and a high of $24.
Nektar Therapeutics (NKTR) estimates and forecasts
The year-over-year growth rate is expected to be 17.53%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 36.66M in revenue for the current quarter. 6 analysts expect Nektar Therapeutics to make 22.39M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 23.89M and 21.64M respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 53.48%. Forecasts for the next quarter put sales growth at 3.47%.
Nektar Therapeutics earnings are expected to increase by 51.03% in 2025, but the outlook is positive 20.18% per year for the next five years.
NKTR Dividends
Nektar Therapeutics’s next quarterly earnings report is expected to be released in April.
BLACKROCK INC., with 7.7823% or 15.16 million shares worth $18.79 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Mutual Fund Ser Tr-Eventide Healthcare & Life Sciences Fund and Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 9.4 shares worth $7.54 million, making up 5.10% of all outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held roughly 5.72 shares worth around $4.59 million, which represents about 3.10% of the total shares outstanding.
